PSA’s limited diagnostic specificity—elevated levels can result from benign conditions, leading to diagnostic bias—and the inevitable progression of all PCa patients from hormone-sensitive to castration-resistant prostate cancer (CRPC) contribute to diminishing treatment efficacy (Wasim et al., 2022). The gene discussed is KLK3; the disease is posterior cortical atrophy.